Stu Fillman Email & Phone Number

Gold Coast, Qld, Au

Apac

Australia And New Zealand

Sydney, Australia

Australia

Anz

• Worked to design role to support the strategy, implementation and diagnostics for all rare diseases. A dedicated resource for all activities involving finding patients• Administered medical screening budget • Authored and revised local SOP on Screening Projects reflecting global guidance and working with local/regional/global stakeholders• Worked with patient groups and physicians on engagement regarding diagnostic issues such as High Risk Testing, Family Screening and Newborn… Show more • Worked to design role to support the strategy, implementation and diagnostics for all rare diseases. A dedicated resource for all activities involving finding patients• Administered medical screening budget • Authored and revised local SOP on Screening Projects reflecting global guidance and working with local/regional/global stakeholders• Worked with patient groups and physicians on engagement regarding diagnostic issues such as High Risk Testing, Family Screening and Newborn Screening• Designed and implemented the first Family Screening program for Fabry disease in a privacy restricted, developed healthcare system• Contracted with the three nation-wide laboratory groups in Australia on handing blood collections for diagnostic testing, biomarkers and genotype confirmation • Identified and negotiated the multinational agreement to import, adapt and utilise diagnostic testing management software to host all diagnostic testing in collaboration with local laboratories• Developed an EMR based screening program to help facilitate the diagnosis of MPS diseases from the GP level • Worked extensively as a cross functional member of both the Rare Disease Leadership team and the various brand teams. • Worked with Market Access on health economic analysis of Newborn Screening• Lead market research project on the use of Next Generation Sequencing Panels for diagnosis of Pompe disease• Performed MA code complaint defense duties and material review Show less

Australia

• One of two in the Genzyme Medical Department supporting 5 diseases and 6 products across all of Australia and New Zealand• Responsible for KOL engagement in variety of specialties including haematology, nephrology, cardiology, neurology, rheumatology and paediatrics• Participated on multiple brand teams as medical representative• Launch partner for new Gaucher treatment• Contract negotiations for Australasian wide testing for rare diseases• Facilitated multiple ISS’s… Show more • One of two in the Genzyme Medical Department supporting 5 diseases and 6 products across all of Australia and New Zealand• Responsible for KOL engagement in variety of specialties including haematology, nephrology, cardiology, neurology, rheumatology and paediatrics• Participated on multiple brand teams as medical representative• Launch partner for new Gaucher treatment• Contract negotiations for Australasian wide testing for rare diseases• Facilitated multiple ISS’s, investigator trials, fellowships and other disease awareness initiatives• Reviewed clinical papers for field usage• Implemented Rare Disease Journal alert service using Campaign Monitor to collect usage data, now best practice across most of Sanofi Australia• Conducted training of Rare Disease sales and marketing staff• Worked with legal and procurement on large scale genetics and patient support projects• Planned medical round table meetings with visiting speakers• Attended conferences while collaborating with sales and marketing colleagues on booths.• Worked in the field with Rare Disease sales representatives• Assisted with the development of marketing plans for Gaucher• Created and sent responses to medical information requests• Reviewed materials from a medical compliance perspective Show less

Schizophrenia Research Laboratory

• Replicated and expanded earlier findings of increased inflammation in a subgroup of people with schizophrenia by incorporating markers of stress (glucocorticoids).• Lead biomarker identification program which found a pattern of cytokines (mRNA and protein) in the blood of patients with schizophrenia defining a subgroup of 40% of individuals with elevated inflammation/immune activation.• Linked this subgroup of individuals with schizophrenia and high inflammation to focal decreases in… Show more • Replicated and expanded earlier findings of increased inflammation in a subgroup of people with schizophrenia by incorporating markers of stress (glucocorticoids).• Lead biomarker identification program which found a pattern of cytokines (mRNA and protein) in the blood of patients with schizophrenia defining a subgroup of 40% of individuals with elevated inflammation/immune activation.• Linked this subgroup of individuals with schizophrenia and high inflammation to focal decreases in brain volume and related cognitive functions.• Evaluated current anti-inflammatory treatments and proposed a new monoclonal antibody based adjunctive treatment paradigm for biological subgroups of schizophrenia• Co-Authored grants and design for proposed therapeutic trial incorporating biomarkers into the subject selection process.• Assisted in analysis of previous clinical trial using a selective estrogen receptor modulator (Raloxifine) as an adjunctive treatment for schizophrenia. Focused on assisting with write-up and statistical interpretation. • Worked with other team members to re-examine data in light of high inflammatory biological subgrouping. This has lead to novel interpretations of astrogliosis and cell migration• Presented data at Australian Neuroscience Society meeting, International Congress of Schizophrenia Research, Profiled in two institute newsletters (Schizophrenia Research Institute and Neuroscience Research Australia). Conducted media interviews for article published in national newspaper. Show less

Schizophrenia Research Laboratory

• Characterised changes in the GABAA receptor which occur both during normal development and in individuals with schizophrenia. Measurements of mRNA expression were performed using qPCR and assembled receptors were quantified using radioligand binding in collaboration with ANSTO. Found significant developmental changes in development as well as increased GABAA receptor binding in individuals with schizophrenia.• Collaborated with Canadian researchers on the development of serotonin… Show more • Characterised changes in the GABAA receptor which occur both during normal development and in individuals with schizophrenia. Measurements of mRNA expression were performed using qPCR and assembled receptors were quantified using radioligand binding in collaboration with ANSTO. Found significant developmental changes in development as well as increased GABAA receptor binding in individuals with schizophrenia.• Collaborated with Canadian researchers on the development of serotonin receptors in the DLPFC of humans. • Lead large Next Generation Sequencing (RNA-Seq) project to examine transcriptome changes in the dorsolateral prefrontal cortex of people with schizophrenia.• Used both public and created custom coded bioinformatics tools for analysis• Identified a number of molecular changes, significantly an upregulation in the inflammatory pathway. • Used novel statistical methods to identify a subgroup of 40% of people with schizophrenia who have elevated markers of inflammation in their brains. Also displayed significant decreases in markers of inhibitory interneurons linking pathologies.• Published in leading psychiatry journal “Molecular Psychiatry” with 30+ citations since 2012.• PhD Thesis: Schizophrenia: A disease mediated by neuroinflammation, neurotransmitters, or both? October 2012• Supervisor: Professor Cyndi Shannon Weickert Show less

Hamilton, Ontario, Canada

• Examined the response of rodent visual cortex to different levels of luminance. • Used EEG recordings of visual evoked potentials which were then analyzed using custom programmed analysis software in Matlab. Special examination of the response characteristics in the gamma band and coding using bursting activity. • Identified substantial non-linear response in the gamma band to increase in luminance level with peak in response power at 3-5cd/m2 and decrease at higher levels. The… Show more • Examined the response of rodent visual cortex to different levels of luminance. • Used EEG recordings of visual evoked potentials which were then analyzed using custom programmed analysis software in Matlab. Special examination of the response characteristics in the gamma band and coding using bursting activity. • Identified substantial non-linear response in the gamma band to increase in luminance level with peak in response power at 3-5cd/m2 and decrease at higher levels. The mechanism of this gamma response changed as luminance level increased with greater inhibition at the high end.• MSc Thesis: The Response to Luminance in the Primary Visual Cortex, S.G Fillman, April 14, 2009• Supervisor: Dr. Kathy Murphy and Dr. David Jones, Committee members: Dr. Bruce Christensen, Dr. David Jones and Dr. Brett Beston. McMaster Institute for Neuroscience Discovery & Study, McMaster University Show less

Hiring, direction and scheduling of 30+ lifeguards and instructorsDesigning and implementing employee trainingEnsuring adherence to codes and best practices

Banff, Alberta, Canada

I ran the day to day operations of the Town of Banff's only publicly accessible pool. Located on the campus of The Banff Centre on Tunnel Mountain we taught lessons, supervised visiting groups to the Centres various artistic programs, and ran public lane/leisure swims. I also was in charge of pool chemistry and maintenance for the facility. I left this rewarding position to pursue my bachelors degree at the University of Guelph

Master Of Business Administration - Mba, Technology

Phd, Psychiatry

Activities and Societies: Biological Psychiatry Australia, Society for Neuroscience

Msc, Neuroscience

Activities and Societies: Canadian Association for Neuroscience, Society for Neuroscience, Neuroscience Students Association

Bsc, Biological Science (Neuroscience)